Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?

التفاصيل البيبلوغرافية
العنوان: Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?
المؤلفون: Richard M. Weinshilboum, Mark A. Frye, Ada Man Choi Ho, Joanna M. Biernacka
المصدر: Pharmacogenomics. 22:913-925
بيانات النشر: Future Medicine Ltd, 2021.
سنة النشر: 2021
مصطلحات موضوعية: Bipolar Disorder, medicine.drug_class, Lamotrigine, Bioinformatics, Antimanic Agents, Genetics, medicine, Humans, Bipolar disorder, Pharmacology, Valproic Acid, Mood Disorders, business.industry, Mood stabilizer, Carbamazepine, Precision medicine, medicine.disease, Treatment Outcome, Mood, Pharmacogenomics, Molecular Medicine, Anticonvulsants, business, Antipsychotic Agents, medicine.drug
الوصف: Antiepileptic mood stabilizers (AED-MS) are often used to treat bipolar disorder (BD). Similar to other mood disorder medications, AED-MS treatment response varies between patients. Identification of biomarkers associated with treatment response may ultimately help with the delivery of individualized treatment and lead to improved treatment efficacy. Here, we conducted a narrative review of the current knowledge of the pharmacogenomics of AED-MS (valproic acid, lamotrigine and carbamazepine) treatment response in BD, including genetic contributions to AED-MS pharmacokinetics. Genes involved in neurotransmitter systems and drug transport have been shown to be associated with AED-MS treatment response. As more studies are conducted, and experimental and analytical methods advance, knowledge of AED-MS pharmacogenomics is expected to grow and contribute to precision medicine in BD.
تدمد: 1744-8042
1462-2416
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e6b2506f04461c08e2c7ecd724d941Test
https://doi.org/10.2217/pgs-2021-0041Test
رقم الانضمام: edsair.doi.dedup.....11e6b2506f04461c08e2c7ecd724d941
قاعدة البيانات: OpenAIRE